Cytovia Therapeutics to present at Jefferies Cell Therapy Virtual Summit, BIO Investor Forum and New York Stem Cell Foundation Conference in October…

NEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics an emerging biopharmaceutical company developing Natural Killer Cell Therapeutics, today announced that it will participate in three key conferences in October 2020.

The Jefferies Cell Therapy Virtual Summit will take place on October 5-6, 2020.Cytovia CEO Dr. Daniel Teper will present on October 6th at 5.30 PM EDT. Webcast link

The BIO Investor Forum will take place on October 13-15, 2020.Cytovia will have an on-demand company presentation during the Bio Investor Forum Digital.

The New York Stem Cell Foundation Conference will take place on October 20-21, 2020.Dr. Wei Li, Cytovia Executive Vice President, R&D and Chief Scientific Officer, will present during the Stem Cell Application in Therapeutics session, on October 21st at 11.15 AM EDT.

The webcast links will be available on the company website and social media pages.

On-demand interview opportunities with Cytovia Therapeutics spokespersons:Daniel Teper, CEO Wei Li, Chief Scientific Officer

ABOUT CYTOVIA THERAPEUTICS:Cytovia Therapeutics Inc is an emerging biotechnology company that aims to accelerate patient access to transformational immunotherapies, addressing several of the most challenging unmet medical needs in cancer and severe acute infectious diseases. Cytovia focuses on Natural Killer (NK) cell biology and is leveraging multiple advanced patented technologies, including an induced pluripotent stem cell (iPSC) platform for CAR (Chimeric Antigen Receptors) NK cell therapy, next-generation precision gene-editing to enhance targeting of NK cells, and NK engager multi-functional antibodies. Our initial product portfolio focuses on both hematological malignancies such as multiple myeloma and solid tumors including hepatocellular carcinoma and glioblastoma. The company partners with the University of California San Francisco (UCSF), the New York Stem Cell Foundation (NYSCF), the Hebrew University of Jerusalem, and CytoImmune Therapeutics. Learn more at http://www.cytoviatx.com and Follow Cytovia on Social Media Facebook, LinkedIn, Twitter.

For more information please contact:Cytovia Therapeutics, IncSophie Badr, Vice President, Corporate Affairs1 (929) 317 1565 sophie.badre@cytoviatx.com

View post:
Cytovia Therapeutics to present at Jefferies Cell Therapy Virtual Summit, BIO Investor Forum and New York Stem Cell Foundation Conference in October...

Aqua-Spark Announces an Investment in Singapore-based Shiok Meats, the First Cell-Based Company to Produce Clean, Sustainable, Cruelty-Free Shrimp and…

New York, NY Aqua-Spark(the Fund), the first investment fund focused on sustainable aquaculture, announced an investment inShiok Meats(Shiok), the worlds first cell-based crustacean meat company based in Singapore. Shiok is the first cell-based meat company in South East Asia, and the first and only cell-based meat company working on shrimp. Their flagship product is a highly-anticipated cell-based shrimp, which offers clean, traceable alternatives to the shrimp farming industry.

Aqua-Spark is the lead investor in Shiok Meats $12.6M Series A round, which also includes investments from SEEDS Capital (the investment arm of Enterprise Singapore), Real Tech Fund (Japan), Irongrey (a Global tech investing family office based in Korea), Yellowdog Empowers Fund (South Korea), Ilshin Holdings Pte. Ltd (Singapore), Toyo Seikan Group Holdings, Ltd (Japan),Veg Invest Trust (USA), Makana Ventures (Singapore), AiiM Partners LP (USA), Beyond Impact (Europe), Kelvin Chan Siang Lin (Singapore), and Alex Payne and Nicole Brodeur (USA). The funds will contribute towards building the first-of-its-kind commercial pilot plant from which Shiok plans to launch its minced shrimp product in 2022. This puts Shiok on schedule to become the first company in the world to have a fully functioning commercial pilot plant for cell-based crustacean production.

Mike Velings and Amy Novogratz, co-founders of Aqua-Spark:

The cell-based animal protein industry has been on our radar for some time as once it is at scale it will have an enormous influence on food production efficiency, food safety, and the environment. As our first investment in cell-based seafood, Shiok Meats immediately stood out to us with their strong, female-led team and impressive milestones to-date. While weve invested in a number of technologies working to make shrimp farming more efficient, healthier, and less polluting, Shiok is the first company in our portfolio to focus on shrimp production. We are excited to help shape this novel and innovative industry, which we expect to have a huge impact on the future of seafood, while continuing to support sustainable aquaculture operations, inputs, and innovations across the value chain.

The shrimp market is a $50 billion market globally with Vietnam, Thailand, Indonesia, and India being the major producers of shrimp. While there are many farms and technologies improving shrimp farming, there is still work to be done. Much of what is currently on the market is raised in crowded factories/farms and treated with antibiotics, chemicals, and hormones. Conventional production processes often contribute to overfishing, excessive bycatch, misrepresentation, and mislabeling as well as contamination with effluents, heavy metals, and microplastics. This form of production is unsustainable and the sector strain will only increase as the population grows. Shiok is addressing this need and disrupting crustacean production to ensure people can eat clean shrimp, crab and lobster from a safe source. Clean meat production could reduce the industrys greenhouse gas emissions by 96 percent, energy consumption by 45 percent, land use by 99 percent, and water consumption by 96 percent.

Shiok Meats was founded in August 2018 by two stem cell scientists, Dr. Sandhya Sriram and Dr. Ka Yi Ling, with over 20 years of combined experience in the muscle, fat, and stem cell biology fields. Shioks mission is to produce clean, healthy, cruelty-free seafood. Their cell-based production process is non-GMO and chemical and antibiotic-free.

Dr. Sandhya Sriram, CEO and co-founder of Shiok Meats:

We are extremely excited to work in partnership with Aqua-Spark as we develop cell-based seafood and meats that are contributing towards a cleaner and healthier seafood industry and solving for the inefficiencies around global protein production. Aqua-Spark was the perfect partner to lead our Series A because they care deeply about funding companies that address planetary health and food security. With their help, we hope to become the global leader in cell-based crustaceans and seafood. We are pleased that Aqua-Spark supports our global impact vision and will be with us for the long haul.

Shiok stands out from other cell-based meat production companies because of their proprietary technology that isolates stem cells from shrimp, lobster, and crabthey are the first company to be able to do this for cell-based production at the moment. Once the stem cells are harvested, the shrimp, lobster, and crab meats are grown in nutrient-rich conditions, similar to that of a greenhouse. After four-to-six weeks, the cell-based seafood is exactly the same as its conventional counterpart but more sustainable, clean, and nutritious. Shioks patent-pending technology can grow crustaceans four times faster than conventional production.

The output of Shioks pilot plant will be frozen cell-based shrimp meat for dumplings and other shrimp-based dishes. Beyond cell-based shrimp, Shiok plans to launch shrimp flavouring paste and powder, fully-formed 3D shrimp, and cell-based lobster and crab products in the coming years.

To date, Aqua-Spark has now invested in 20 complementary companies, technologies, and inputs that are working toward the sustainable production of aquatic life.

About Aqua-Spark

Launched in 2011, Aqua-Spark is an investment fund with a mission to transform the global aquaculture industry into one that is healthier, more sustainable, and more accessible. They invest in aquaculture companies across the value chainspanning farming operations, alternative feed ingredients, disease-battling technology, and consumer-facing aquaculture products. These companies are solving some of the industrys big challenges while bringing returns that are comparable to todays traditional industry. The portfolio works as an ecosystem, with the companies agreeing to collaborate on optimal solutions, and working together toward this shared vision of a more efficient global aquaculture industry.

Since 2015, the fund has invested in 20 complementary SMEs. Thus far, Aqua-Spark has EUR 152 million in assets under management, dedicated to investments in elements of the aquaculture industry that will make fish farming sustainable. The goal of the fund is to ultimately make sustainability widespread and profitable enough that it becomes the only way to farm fish.

About Shiok Meats

Shiok Meats is a cell-based, clean meat company. It is the first of its kind in Singapore and South-East Asia with a mission to deliver delicious, clean, and healthy seafood by harvesting from cells instead of animals. Shiok Meats is working to bring cell-based crustacean meats (shrimp, crab, lobster) to the kitchen. Their meats are cruelty-free, healthy, and better for the environment with the same taste and texture and more nutrients than their traditional counterparts.

Go here to read the rest:
Aqua-Spark Announces an Investment in Singapore-based Shiok Meats, the First Cell-Based Company to Produce Clean, Sustainable, Cruelty-Free Shrimp and...

President Trump Is Taking an Experimental COVID Treatment Not Approved by the FDA – VICE

U.S. President Donald Trump walks on the South Lawn of the White House after arriving on Marine One in Washington, D.C., U.S., Thursday, Oct. 1, 2020. (Photo: Yuri Gripas/Abaca/Bloomberg via Getty Images)

President Trump has taken a significant dose of an experimental treatment for COVID-19 that hasnt yet been approved by the Food & Drug Administration.

Trump will be moved to Walter Reed National Military Medical Center and plans to remain there for a few days, the White House said Friday.

Taken together, Friday evening presented the astonishing spectacle of a sitting American president being rushed to the hospital hours after announcing he tested positive for the novel coronavirus, while taking a drug so new that its not generally available for public use.

Hes been given an experimental drug that shows promise, said Dr. Jeanne Marrazzo, Director of infectious diseases at University of Alabama, Birmingham.

The drug hasnt even received emergency use authorization from the FDA, which is normally how an early drug would be accessible to a patient.

It hasnt got any kind of FDA authorization, Marrazzo said. The only way people would normally be able to get this is by participating in a clinical trial.

The drug ranks as one of the most promising treatments available for COVID-19, medical experts say, although it hasnt yet received extensive testing. Marrazzo said shes only aware of a single, public, randomized trial involving some 275 participants. But she cautioned that the company, and the federal government, may have more data that hasnt yet been made public.

Trump has been given a single eight-gram dose of an antibody cocktail made by the drugmaker Regeneron, the White House said in a statement Friday.

Trump got the drug through whats known as a compassionate use exception, Regeneron said, in which a sick patient can be granted access to a drug thats not yet approved by the FDA outside of a clinical trial.

The companys CEO, Leonar Schleifer, told The New York Times in an interview that Trumps medical staff reached out to the company for permission to use the drug, and that the FDA cleared the request.

All we can say is that they asked to be able to use it, and we were happy to oblige, Schleifer told the Times. When its the president of the United States, of course, that gets obviously gets our attention.

Giving Trump the drug at this stage is probably safe, said Jonathan D. Dinman, chair of the Department of Cell Biology and Molecular Genetics at the University of Maryland. But monoclonal antibodies could, in theory, trigger an autoimmune response, in which the body begins to attack itself.

I think its a pretty low-risk approach, Dinman told VICE News. Were pretty good at making monoclonal antibodies that have a minimal side effect.

The point of dosing the president with a cocktail of antibodies would be to try and reduce the amount of virus in Trumps body before they replicate too far, Dinman said.

Its like throwing a bucket of water on a fire thats just begun. Youre hoping you knock it out. though it might not, Dinman said. Hes already tested positive, so the virus is already established. That means we dont know if the bucket of water is big enough.

Read the original:
President Trump Is Taking an Experimental COVID Treatment Not Approved by the FDA - VICE

Global Single Cell Multi-Omics Market 2020 One the most booming industry in forthcoming years due to worldwide demand in Coronavirus (COVID-19)…

Global Single Cell Multi-Omics Market Analysis Providing Latest Market Trends And Developments

TheSingle Cell Multi-Omics Marketreport is a compilation of market analysis, qualitative & quantitative industry analysis, and import & export study. Furthermore, the research report also provides an in-depth analysis of the key market trends, economic status, growth drivers, and market strategies for the better understanding of the third party. The report is made attractive through the immense data being offered through each and every segment. The qualitative impact of the market opportunities and restraints on every segment and region is also mapped in a precise manner.

Get Exclusive PDF Sample Copy Of This Report@https://www.marketdataanalytics.biz/global-single-cell-multi-omics-market-industry-trends-and-27433.html#request-sample

The Single Cell Multi-Omics market report provides all the precisely studied and assessed data of the key market players and their scope in the industry. Some of the key market players include10x Genomics, 1CellBio, MissionBio, NanoString Technologies, Fluidigm Corporation, Fluxion Biosciences, Bio-Rad Laboratories, Celsee, BGI Genomics, GE LifeSciences, Illumina, Takara Bio, QIAGEN N.V.. There is an elaborate explanation about the key strategic developments of the market, regional growth of the key players, product launches, and other factors in the report. Other key market growth indicators such as gross margin, share & revenue, supply & demand, and production rate are also mentioned in the Single Cell Multi-Omics market research report.In addition, the study incorporates a comprehensive study of the major market dynamics and their latest trends, along with appropriate market segments and sub-segments.

Product Type analysis:Single Cell Genomics, Single Cell Proteomics, Single Cell Transcriptomics, Single Cell Metabolomics

Application analysis:Oncology, Cell Biology, Neurology, Immunology, Others

Similarly, the regional players North America (U.S., Canada, Mexico), South America (Cuba, Brazil, Argentina, and many others.), Europe (Germany, U.K., France, Italy, Russia, Spain, etc.), Asia (China, India, Russia, and many other Asian nations.), Pacific region (Indonesia, Japan, and many other Pacific nations.), Middle East & Africa (Saudi Arabia, South Africa, and many others.) also aids in understanding the market position on the global and regional platform.

Complete report information along with sample/table of contents available::https://www.marketdataanalytics.biz/global-single-cell-multi-omics-market-industry-trends-and-27433.html

Major points of the Single Cell Multi-Omics market report:

Complete assessment of all opportunities and challenges in the Single Cell Multi-Omics market Single Cell Multi-Omics market present developments and future trends Comprehensive study of trade strategies for growth of the Single Cell Multi-Omics key market players Detailed study of the market growth factors for the forthcoming years In-depth understanding of Single Cell Multi-Omics market drivers, challenges, and key micro markets. Favorable factors inside dynamic technological and market latest trends striking the Single Cell Multi-Omics market

This report can be customized as per your needs for additional data. The Single Cell Multi-Omics market research report provides the statistical forecasts, detailed segmentation, competitive landscape, key trends, and strategic recommendations, thereby providing a 360 degree view of the market.

Place Inquiry for Buying or Customization of Report:https://www.marketdataanalytics.biz/global-single-cell-multi-omics-market-industry-trends-and-27433.html#inquiry-for-buying

About Us

Market Data Analytics is a leading global market research and consulting firm. We focus on business consulting, industrial chain research, and consumer research to help customers provide non-linear revenue models. We believe that quality is the soul of the business and that is why we always strive for high quality products. Over the years, with our efforts and support from customers, we have collected inventive design methods in various high-quality market research and research teams with extensive experience.

View original post here:
Global Single Cell Multi-Omics Market 2020 One the most booming industry in forthcoming years due to worldwide demand in Coronavirus (COVID-19)...

Genetics may contribute to weight gain after switching from efavirenz to an integrase inhibitor – aidsmap

Genetic variations in a liver enzyme could explain why some people put on unwanted weight after switching from efavirenz to an integrase inhibitor, Dr Michael Leonard of Vanderbilt University Medical Center in Nashville and colleagues report in Clinical Infectious Diseases. Slow metabolism of efavirenz due to the CYP2B6 gene leading to higher blood concentrations of the drug was associated with greater weight gain after switching from efavirenz to some integrase inhibitors.

The second part of the study showed that among people starting HIV treatment for the first time, taking efavirenz with tenofovir (TDF) rather than abacavir was associated with less weight gain, even in the context of CYP2B6 and efavirenz concentrations.

Our findings suggest that TDF exposure in the presence of higher efavirenz concentrations interferes with expected weight gain, write the authors. A known TDF side effect is loss of appetite. The association with efavirenz may only be apparent with concomitant TDF-related appetite suppression.

A class of antiretroviraldrugs. Integrase strand transfer inhibitors (INSTIs) block integrase, which is an HIV enzyme that the virus uses to insert its genetic material into a cell that it has infected. Blocking integrase prevents HIV from replicating.

Defines who cannot take part in a research study. Eligibility criteria may include disease type and stage, other medical conditions, previous treatment history, age, and gender. For example, many trials exclude women who are pregnant, to avoid any possible danger to a baby, or people who are taking a drug that might interact with the treatment being studied.

Statistical tests are used to judge whether the results of a study could be due to chance and would not be confirmed if the study was repeated. If result is probably not due to chance, the results are statistically significant.

The physical and chemical reactions that produce energy for the body. Metabolism also refers to the breakdown of drugs or other substances within the body, which may occur during digestion or elimination.

A protein which speeds up a chemical reaction.

People often experience weight gain due to a return to health effect when beginning HIV treatment. Specific anti-HIV medications, including integrase inhibitors, are associated with greater weight gain than other regimens. There is more research on weight gain after starting treatment than after switching to a different regimen.

Treatment guidelines recommend integrase inhibitors for first-line antiretroviral therapy. They include bictegravir, dolutegravir, elvitegravir and raltegravir. Their potency and side-effect profile also make them a good choice for people who need to change their HIV treatment because of virological failure or side effects. For many years, efavirenz was a mainstay of HIV therapy. But the drug can cause neuropsychological side effects. Large numbers of individuals have therefore switched from efavirenz to an integrase inhibitor. Unwanted weight gain has been observed among some people making this switch.

The investigators wanted to find out why. They hypothesised that it could be down to genetics, especially the role of specific genetic mutations or polymorphisms in the metabolising of efavirenz and integrase inhibitors.

The CYP2B6 polymorphism is associated with the processing of efavirenz, and slow metabolising of the drug can lead to high blood concentrations, leading to neuropsychological side effects. A polymorphism called UGT1A1 can affect the speed with which the body processes integrase inhibitors but its effect on weight gain is unknown.

To test if their theory was correct they studied two different groups of people living with HIV. Group 1 included 61 individuals with an undetectable viral load, who had been taking efavirenz for two years and switched to an integrase inhibitor. They had blood tests to determine how the CYP2B6 polymorphism affected blood concentrations of efavirenz. Weight gain 48 weeks after switching to an integrase inhibitor was examined.

Group 2 comprised 462 HIV-positive individuals who were starting antiretroviral therapy for the first time. They were treated with efavirenz in combination with either TDF/emtricitabine or abacavir/lamivudine. Genetic characteristics, drug metabolism and weight gain 48 weeks after treatment initiation were assessed.

In the first group, weight increased by an average of 2kg after switching from efavirenz to an integrase inhibitor. The extent of this increase differed according to race. The median weight gain was higher among Black individuals (3kg) than White individuals (2kg).

After taking into account factors such as age and sex, the investigators found a statistically significant relationship between slow metabolising of efavirenz (and therefore higher concentrations) related to CYP2B6 and weight gain (p = 0.001). This finding was weakened when the investigators excluded from their analysis an individual who gained 27kg in the year after making the treatment change.

Weight gain after the treatment switch differed between specific integrase inhibitors and was present for elvitegravir and raltegravir but not dolutegravir. But even for elvitegravir and raltegravir, the association was weakened and was no longer statistically significant when the person with extreme weight gain was excluded from analysis.

There was no evidence that the UGT1A1 polymorphism was associated with weight gain.

The above findings suggested that events that preceded switching affected weight gain after switching, as CYP2B6 does not metabolize integrase inhibitors, comment the authors.

The relationship between CYP2B6, processing of efavirenz and weight gain was further suggested by analysis of the individuals who were starting HIV therapy for the first time. But the extent of weight gain after 48 weeks of treatment differed according to the treatment backbone and individuals taking TDF/emtricitabine had significantly less weight gain (p = 0.001) than people treated with abacavir/lamivudine.

Among patients who switched from efavirenz- to integrase-inhibitor-based therapy, CYP2B6 genotype was associated with change in weight at week 48, likely because greater efavirenz exposure causes less weight gain during the pre-switch regimen, conclude Dr Leonard and his co-authors. They were unable to explain why the risk of weight gain among people starting treatment differed between TDF and abacavir.

The rest is here:
Genetics may contribute to weight gain after switching from efavirenz to an integrase inhibitor - aidsmap

Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics…

This article was originally published here

JCO Oncol Pract. 2020 Sep 28:OP2000431. doi: 10.1200/OP.20.00431. Online ahead of print.

ABSTRACT

Germline genetic testing is now routinely recommended for patients with prostate cancer (PCa) because of expanded guidelines and options for targeted treatments. However, integrating genetic testing into oncology and urology clinical workflows remains a challenge because of the increased number of patients with PCa requiring testing and the limited access to genetics providers. This suggests a critical unmet need for genetic services outside of historical models. This review addresses current guidelines, considerations, and challenges for PCa genetic testing and offers a practical guide for genetic counseling and testing delivery, with solutions to help address potential barriers and challenges for both providers and patients. As genetic and genomic testing become integral to PCa care, developing standardized systems for implementation in the clinic is essential for delivering precision oncology to patients with PCa and realizing the full scope and impact of genetic testing.

PMID:32986533 | DOI:10.1200/OP.20.00431

See the article here:
Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics...

Using Genetics to Increase Specificity of Outcome Prediction in Psychiatric Disorders: Prospects for Progression | American Journal of – Am J…

Using Genetics to Increase Specificity of Outcome Prediction in Psychiatric Disorders: Prospects for Progression | American Journal of  Am J Psychiatry

See the article here:
Using Genetics to Increase Specificity of Outcome Prediction in Psychiatric Disorders: Prospects for Progression | American Journal of - Am J...

PD GENEration Study Now Includes At-home Genetic Testing and… – Parkinson’s News Today

The Parkinsons Foundation has expanded its PD GENErationnational study to include at-home genetic testing and virtual counseling inSpanish as well as English.

Opened in 2019 through the organization and partly supported by Biogen, PD GENEration offers Parkinsons (PD) patients free genetic testing plus genetic counseling to help them understand test results.

To remove barriers to Parkinsons research participation in the underserved Hispanic population, the Parkinsons Foundation decided to offer patientsat-home testing and counseling in Spanish. The study seeks to use the testing to boost clinical trial enrollment. In turn, researchers hope to use test results to develop treatment candidates and personalized therapeutic approaches.

We want the Hispanic community to know that they can be empowered by taking part in the PD GENEration program and that their voices and experiences are incredibly valuable in helping us move the field forward for the entire PD community, said Ignacio Mata, PhD, chair of the Parkinsons Foundation Hispanic Parkinsons Advisory Council, in a press release.

Offering the study in Spanish is critical to ensuring that the Hispanic community can easily participate and therefore will be well represented in this important study, Mata said.

After a virtual screening appointment to confirm eligibility, prospective PD GENEration participants schedule a two-hour virtual testing appointment. During that appointment, and with guidance from a healthcare professional, patients complete the genetic assessment.Test results are discussed with a counselor during a follow-up phone appointment.

To determine participation eligibility, go here for a short online questionnaire. For questions about enrollment, write to [emailprotected].

The Parkinsons Foundation has adapted to help the PD community gain access to this valuable and empowering information from the safety and comfort of their homes during the ongoing COVID-19 pandemic and beyond, said James Beck, PhD, the organizations chief scientific officer. We are looking forward to continuing this research study so that we may one day soon be able to provide precision treatments for the 1 million Americans living with Parkinsons disease.

Genetic testing and counseling will remain available at six in-person testing sites nationwide. The Foundation expects to add 10 testing sites next year.

In addition to identifying potential clinical trial participants, such testing can help scientists uncover underlying Parkinsons mechanisms, which could lead to improved treatments and patient care. Understanding genetic differences across people with Parkinsons can help reveal the diseases variable effect.

As it stands, genetic tests for Parkinsons often are unaffordable and not covered by insurance. And, many dont offer genetic counseling, which can help interpret test results. Consequently, most Parkinsons patients dont know whether they carry genetic changes in Parkinsons-related genes. The PD GENEration study seeks to address this need.

Early study results show that comprehensive genetic testing and counseling, and the identification of rare genetic mutations linked to the disease, is practicable for the Parkinsons community at large.

Roughly 15% of Parkinsons cases may be associated with genetic mutation.Since its launch, the PD GENEration study has tested at least 291 people, 52 of whom tested positive for a Parkinsons-related mutation.

The study tests for the following genes with known Parkinsons associations: GBA(glucocerebrosidase beta),LRRK2(dardarin),PRKN(Parkin),PINK1(PTEN induced putative kinase 1),PARK7(DJ-1),VPS-35,andSNCA(alpha-synuclein).

To date, some study participants tested have shown extremely rare mutations, with some individuals even carrying multiple Parkinsons-associated mutations. This information should contribute to a better understanding of the neurodegenerative disorder.

Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours dElegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled Belle of the Concours.

Total Posts: 208

Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.

More here:
PD GENEration Study Now Includes At-home Genetic Testing and... - Parkinson's News Today

Fulgent Genetics Announces Partnership with Ohio Department of Rehabilitation and Correction for COVID-19 TestingFulgent Genetics will provide routine…

TEMPLE CITY, Calif., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent Genetics or the company), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that the Ohio Department of Rehabilitation and Correction (ODRC) has selected Fulgent Genetics for their COVID-19 testing needs.

The Ohio Department of Rehabilitation and Correction will leverage Fulgents RT-PCR testing capabilities and Enterprise Platform to test its approximately 14,000 employees on a routine basis. The partnership encompasses on-site testing at locations across the state and will leverage Fulgents Enterprise Platform. Fulgents platform will enable theODRC to streamline the on-site testing process by either giving each employee a QR code or using their employer ID which is linked to the individuals sample via a barcode scan, and then self-collected under supervision and returned to Fulgents lab for processing and reporting. Employees will receive their results within 24 hours of sample receipt.

We look forward to aiding the Ohio Department of Rehabilitation and Correction in their effort to protect their employees and curb the spread of COVID-19 across their facilities, commented Brandon Perthuis, Chief Commercial Officer of Fulgent Genetics. Our Enterprise Platform offering enables the ODRC to test their employees in an extremely efficient manner, a process that takes approximately one minute per person. This offering provides a flexible and comprehensive testing solution for the ODRC that utilizes our gold-standard RT-PCR testing capabilities. Fulgent continues to raise the bar in offering COVID-19 testing solutions that meet the needs of large organizations and municipalities in a highly efficient and accurate manner.

About Fulgent Genetics

Fulgent Genetics proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing (NGS) with its technology platform, the company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. In 2019, the company launched its first patient-initiated product, Picture Genetics, a new line of at-home screening tests that combines the companys advanced NGS solutions with actionable results and genetic counseling options for individuals. Since March 2020, the company has commercially launched several tests for the detection of SARS-CoV-2, the virus that causes the novel coronavirus (COVID-19), including NGS and reverse transcription polymerase chain reaction (RT-PCR) - based tests. The company has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the RT-PCR-based tests for the detection of SARS-CoV-2 using upper respiratory specimens (nasal, nasopharyngeal, and oropharyngeal swabs) and for the at-home testing service through Picture Genetics. A cornerstone of the companys business is its ability to provide expansive options and flexibility for all clients unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated lab services.

About Picture Genetics

Through its Picture Genetics platform launched in 2019, Fulgent Genetics offers consumers direct access to its advanced genetic testing and analytics capabilities from the ease and comfort of home, at an affordable price point. The Picture Genetics platform provides a holistic approach to at-home genetic screening by including oversight from independent physicians as well as genetic counseling options to complement Fulgent Genetics comprehensive genetic testing analysis. The Picture Genetics platform currently offers multiple tests, providing medically actionable, clinical-level results with professional medical follow-up in one easy process. Visit http://www.picturegenetics.com for more information.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements in this press release include statements about, among other things: managements beliefs, judgments and estimates regarding Fulgents testing solutions, including its technology platforms and RT-PCR testing solution; the companys identification and evaluation of opportunities and its ability to capitalize on opportunities to grow its business; and its expected lab capacity and results turnaround times.

Forward-looking statements are statements other than historical facts and relate to future events or circumstances or the companys future performance, and they are based on managements current assumptions, expectations and beliefs concerning future developments and their potential effect on the companys business. These forward-looking statements are subject to a number of risks and uncertainties, which may cause the forward-looking events and circumstances described in this press release to not occur, and actual results to differ materially and adversely from those described in or implied by the forward-looking statements. These risks and uncertainties include, among others: the ongoing impacts of the COVID-19 pandemic, including the preventive public health measures that may continue to impact demand for its tests and the pandemics effects on the global supply chain; the market potential for, and the rate and degree of market adoption of, the companys tests, including its newly-developed tests for COVID-19 and genetic testing generally; the companys ability to capture a sizable share of the developing market for genetic and COVID-19 testing and to compete successfully in these markets, including its ability to continue to develop new tests that are attractive to its various customer markets, its ability to maintain turnaround times and otherwise keep pace with rapidly changing technology; the companys ability to maintain the low internal costs of its business model, particularly as the company makes investments across its business; the companys ability to maintain an acceptable margin on sales of its tests, particularly in light of increasing competitive pressures and other factors that may continue to reduce the companys sale prices for and margins on its tests; risks related to volatility in the companys results, which can fluctuate significantly from period to period; risks associated with the composition of the companys customer base, which can fluctuate from period to period and can be comprised of a small number of customers that account for a significant portion of the companys revenue; the companys ability to grow and diversify its customer base and increase demand from existing and new customers; the companys investments in its infrastructure, including its sales organization and operational capabilities, and the extent to which these investments impact the companys business and performance and enable it to manage any growth it may experience in future periods; the companys level of success in obtaining coverage and adequate reimbursement and collectability levels from third-party payors for its tests; the companys level of success in establishing and obtaining the intended benefits from partnerships, joint ventures or other relationships; the companys compliance with the various evolving and complex laws and regulations applicable to its business and its industry; risks associated with the companys international operations; the companys ability to protect its proprietary technology platform; and general industry, economic, political and market conditions. As a result of these risks and uncertainties, forward-looking statements should not be relied on or viewed as predictions of future events.

The forward-looking statements made in this press release speak only as of the date of this press release, and the company assumes no obligation to update publicly any such forward-looking statements to reflect actual results or to changes in expectations, except as otherwise required by law.

The companys reports filed with the U.S. Securities and Exchange Commission (SEC), including its annual report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 13, 2020 and the other reports it files from time to time, including subsequently filed quarterly and current reports, are made available on the companys website upon their filing with the SEC. These reports contain more information about the company, its business and the risks affecting its business.

Investor Relations Contact:The Blueshirt GroupNicole Borsje, 415-217-2633; nborsje@blueshirtgroup.com

Media Contact:The Blueshirt GroupJeff Fox, 415-828-8298, jeff@blueshirtgroup.com

Visit link:
Fulgent Genetics Announces Partnership with Ohio Department of Rehabilitation and Correction for COVID-19 TestingFulgent Genetics will provide routine...